A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
about
Sickle cell trait and sudden death--bringing it homeSatisfaction is not all--patients' perceptions of outcome of general practice consultations, a qualitative study.Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulinCost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in ChinaDevelopment of an economic evaluation of diagnostic strategies: the case of monogenic diabetesGetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world.Development of life-expectancy tables for people with type 2 diabetesTemporal validation of the UKPDS outcomes model using 10-year posttrial monitoring dataTowards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data.UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.A critical review of mathematical models and data used in diabetology.Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.A cost effectiveness study of integrated care in health services delivery: a diabetes program in Australia.Indirect estimation of a discrete-state discrete-time model using secondary data analysis of regression data.Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10)Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.The cost-effectiveness of continuous glucose monitoring in type 1 diabetes.Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis.Chronic disease modeling and simulation software.Leukocyte telomere length in the Finnish Diabetes Prevention Study.Cost-effectiveness of health-related lifestyle advice delivered by peer or lay advisors: synthesis of evidence from a systematic reviewStudy protocol: a multi-professional team intervention of physical activity referrals in primary care patients with cardiovascular risk factors--the Dalby lifestyle intervention cohort (DALICO) study.Validation of the IHE Cohort Model of Type 2 Diabetes and the impact of choice of macrovascular risk equationsCluster randomized controlled trial of a peer support program for people with diabetes: study protocol for the Australasian Peers for Progress study.Estimated incidence of cardiovascular complications related to type 2 diabetes in Mexico using the UKPDS outcome model and a population-based survey.Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UKCost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in swedenType 2 diabetes patients' preferences and willingness to pay for lifestyle programs: a discrete choice experimentMoving beyond cardio: the value of resistance training, balance training, and other forms of exercise in the management of diabetes.Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitusCost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metforminThe role of the electronic medical record in the assessment of health related quality of life.Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.Prioritization of care in adults with diabetes and comorbidity.Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System PerspectiveCost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial.HeLP-Diabetes: randomised controlled trial protocolEarly Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Euro
P2860
Q24651083-DE6564A0-D5DF-4C84-821C-0C8D24500BBDQ24812781-5F823080-128B-4F27-B3AA-D833572E36B4Q28268410-7EBA9234-4348-4BF3-AB90-6AE63332F65CQ28553675-E7A5DA73-08C4-4A62-9BD7-DC240F52549DQ28689671-A319463B-FE8F-41CA-B466-9CB7D46E89AFQ30248472-380B3743-E29B-4C9E-8955-3DC205EB19E1Q30486759-D3C7B683-7263-42C9-824E-8B111825F509Q30583586-55DADF88-8AA4-4B34-8846-DD5483DCD6EDQ30625765-C4701DF9-71FB-4DCB-8CBD-0A9FEB815D9CQ30651159-C956701B-9091-4E97-8388-B513B188FD64Q30863970-496E9C8D-7DFE-43B9-8326-343602F4A520Q31047512-32297A64-C5CC-4333-801E-662AC41D9081Q31049802-798B697F-C197-44BC-9275-4F4E01259196Q33373856-06F6D7BF-5BEC-4EF9-9694-ADE84B36BE8CQ33448660-D5BD3E0D-6676-4BB2-91A0-540051870A53Q33497934-5FE9E0FB-247F-422E-A588-F4C9200754A8Q33732593-6BD35517-19D6-488D-B217-4FFCC0A25584Q33751401-30B0E8EC-1199-4F8B-BDB0-253850AA3640Q33873097-F6672D93-6129-468F-B1C0-4B964BF32709Q34077174-1A03EE3E-05DC-45BD-B8B8-A40BDF82BDB7Q34108081-7FC275D0-54A2-4B12-96C9-C26170393851Q34228543-16AD2D7E-33DD-4759-8F33-A3E5C97A2E14Q34245935-FC5A137A-281B-4D7D-9E37-76FD0755C690Q34315071-F9B50543-D8A7-48FD-9FDC-9F973DDC9A1CQ34332236-79385C1B-FDF7-4F26-9963-AA2E26C62FCFQ34433438-DEC827D5-C0E0-41E9-BA42-36014DAF7CBAQ34503859-26575DDE-FC3F-4716-8919-EA92467868DBQ34726520-1E4BC69B-D097-439D-BFA4-848DA731877BQ34726534-26D6DC4E-3A33-4954-80DC-B974011B8E38Q35056770-78184442-8F41-4781-938C-763F20B22485Q35100198-590052D3-5EBA-4643-9B49-99A3BA90AA29Q35528766-A3B0B982-67D3-413B-90D2-C39D37604213Q35551069-3EBBBC23-B3F9-4FDB-BF5D-E161BADFA617Q35625256-5D4E77CE-AF9E-4BE8-A8B3-5D2FEF782D3AQ35717211-3387AC3C-13C4-4749-9EB3-3364B0075F82Q35798114-0CCAF603-829B-4CD9-8A7B-B434B0496281Q35833876-D51412C6-D702-4DD3-BF1F-E76D4879E150Q35877943-78841411-804B-48AA-B385-AA0217CEE361Q35881132-2BC67AAD-B0F3-4621-AF67-1AAAC8242893Q35881450-7CDF52AA-89D4-47AC-AA50-E8FF13C7BE1D
P2860
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
A model to estimate the lifeti ...... Outcomes Model (UKPDS no. 68).
@en
type
label
A model to estimate the lifeti ...... Outcomes Model (UKPDS no. 68).
@en
prefLabel
A model to estimate the lifeti ...... Outcomes Model (UKPDS no. 68).
@en
P2093
P50
P1433
P1476
A model to estimate the lifeti ...... Outcomes Model (UKPDS no. 68)
@en
P2093
A J Farmer
D R Matthews
R J Stevens
UK Prospective Diabetes Study (UKDPS) Group
P2888
P304
P356
10.1007/S00125-004-1527-Z
P577
2004-10-27T00:00:00Z